Myriad Genetics Enhances Breast Cancer Research with Collaborations
Myriad Genetics Expands Research Collaborations for Breast Cancer Testing
Myriad Genetics, Inc. (NASDAQ: MYGN), a pioneer in genetic testing and precision medicine, has recently embarked on a series of important research collaborations aimed at studying the application of molecular residual disease (MRD) testing in breast cancer. These initiatives leverage Myriad’s innovative Precise MRD test to advance the understanding and treatment of this prevalent disease.
Details of the Research Collaborations
The collaborations encompass several significant studies, each focusing on different aspects of breast cancer and ctDNA (circulating tumor DNA) testing. One notable project evaluates whether ctDNA levels can predict the response to treatments such as pembrolizumab combined with hormonal therapy in patients diagnosed with HR-positive inflammatory breast cancer. This study is led by Bora Lim, MD, at The University of Texas MD Anderson Cancer Center.
Correlating ctDNA with Nodal Involvement
Another collaborative effort directed by Anna Weiss, MD, at The University of Rochester Medical Center, seeks to determine the relationship between ctDNA levels and lymph node involvement in newly diagnosed HR-positive breast cancer patients. The findings may influence surgical decisions and improve outcomes for patients.
MONITOR-breast Study Overview
A larger, multicenter prospective study known as MONITOR-breast aims to assess the relationship between ctDNA levels and both neoadjuvant and adjuvant therapies for breast cancer patients across various subtypes. Involving around 650 participants, this study will evaluate the prognostic capabilities of ctDNA as well as its potential to detect recurrences earlier than current imaging standards.
Innovative Approaches in Therapy Guidance
Additionally, the JBCRG-C11 (CREA) study focuses on the effectiveness of maintaining complete response with trastuzumab deruxtecan (T-DXd) in patients with advanced HER2-positive breast cancer. This research tests whether ctDNA can provide optimal therapeutic guidance, led by Yoichi Naito, MD, at the National Cancer Center Hospital East in Japan.
Community Oncology Insights
In collaboration with Aptitude Health, another research project is assessing ctDNA levels in high-risk breast cancer patients at diagnosis and during treatment, including follow-ups after surgery and in community oncology settings. This initiative aims to understand better the role of ctDNA in standard cancer care practices.
Advancements in MRD Testing
The challenge of detecting ctDNA in breast cancer, which typically presents lower ctDNA levels compared to other cancers, has led Myriad Genetics to focus on refining its Precise MRD test. According to Dale Muzzey, chief scientific officer at Myriad Genetics, this test can track up to 1,000 tumor-specific variants through whole-genome sequencing, thus improving sensitivity and accuracy in monitoring patients.
Myriad’s commitment to developing the Precise MRD test aims to fulfill the needs of cancer patients, academic researchers, and biopharmaceutical companies. This vision includes maintaining ongoing partnerships and expanding the application of MRD testing in clinical settings.
About Myriad Genetics
Myriad Genetics stands at the forefront of genetic testing and precision medicine. The company is devoted to enhancing health outcomes through its innovative tests, which identify the risk of disease development and progression. These insights guide treatment decisions across various medical fields, enabling healthcare practitioners to provide better care while also reducing overall costs.
To learn more about Myriad’s offerings and research initiatives, visit their official website.
Frequently Asked Questions
What is MRD testing?
MRD testing refers to the detection of molecular residual disease, particularly assessing ctDNA levels to monitor the presence of cancer after treatment.
How does Myriad’s Precise MRD test work?
The Precise MRD test utilizes whole-genome sequencing to track tumor-specific variants, providing high sensitivity for ctDNA detection.
What are the goals of the recent collaborations announced by Myriad?
The collaborations aim to enhance understanding of ctDNA in breast cancer treatment, improve patient outcomes, and validate the clinical application of MRD tests.
Who leads the various studies involving Myriad's MRD test?
Various prominent researchers and institutions, such as MD Anderson Cancer Center and the National Cancer Center Hospital, are leading the studies.
Why is ctDNA testing more challenging in breast cancer?
Breast cancer often exhibits lower levels of ctDNA in circulation compared to other cancers, complicating the detection process.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- NOVONIX Partners with ICoNiChem for Sustainable Battery Materials
- ThreeD Capital Expands Investor Relations with New Agreement
- Regional Management Corp. Enhances Financial Flexibility with New Credit Agreement
- Kneat Partners with Global Pharma to Transform Validation Processes
- Emergent BioSolutions Enhances Access to NARCAN® for All
- CD47 Inhibitors Market Growth Driven by Innovative Cancer Treatments
- Pfizer's CEO Engages with Starboard Value for Strategic Shift
- Unifor Begins Negotiations with Canadian Pacific Kansas City
- Colliers Engineering Expands with Acquisition of TTM Group
- Kneat Partners with Global Pharma for Enhanced Validation Solutions
Recent Articles
- Investigation Launched for Fortrea Holdings Inc. - What You Need to Know
- HAPO Community Credit Union's Strategic Acquisition Move
- AvidXchange Schedules Third Quarter 2024 Financial Update
- Investigation into SAP SE Sparks Interest Among Investors
- PrairieSky Royalty Unveils Q3 2024 Conference Call Details
- Vicor Corporation Announces Earnings Call for Investors
- LTC Global Expands Its Portfolio with LTCR Acquisition
- Saratoga Investment's Impressive Q2 2025 Financial Performance
- TC Energy's Cash Tender Offers: A Comprehensive Overview
- Square Unveils Innovative Orders Platform for Sellers
- AvidXchange to Release Third Quarter Financial Results Soon
- Andy Florance Honored as a 2024 Tech Titan for Innovation
- FutureFuel Set to Reveal Exciting Q3 2024 Financial Insights
- Empowering Older Women Voters to Shape Pennsylvania's Future
- ImmuCell Reports Strong Sales Growth in 2024 Q3 Performance
- Atlassian Set to Unveil First Quarter FY 2025 Results Soon
- T2 Biosystems Plans Key Business Update Call Soon
- Chalice Medical's CMO8 Oxygenator: A Game Changer for Healthcare
- Palmer Square Capital BDC Plans Earnings Call for Q3 2024 Results
- Investigation into Securities Claims for Lions Gate Shareholders
- Vicor Corporation's Upcoming Earnings Call Details Revealed
- Zeta Global Expands Market Reach with LiveIntent Acquisition
- Washington Trust Bancorp Sets Key Dates for Q3 Earnings Call
- Unlocking Passive Income: The Role of Dividend ETFs Explained
- Morgan Stanley Direct Lending Fund Prepares for Q3 Earnings Call
- Public Voting Launches for Los Angeles Auto Show Awards
- Kinsale Capital Group Set to Share Q3 2024 Financial Results
- Understanding Ciena's Stock Performance and P/E Ratio
- EPAM Systems Plans Conference Call for Q3 Financial Results
- Crocs' Strategic Moves Boost Stock: Should You Invest Now?
- Class Action Opportunity for Metagenomi, Inc. Investors Unveiled
- Exciting Developments: Saxum Real Estate Launches New Cold Storage
- Tesla's Robotaxi Vision Sparks Debate on Autonomous Vehicles
- CarParts.com to Discuss Q3 Financial Results on Upcoming Call
- AGNC Investment Corp. Sets Third Quarter Earnings Release Date
- Third Dimension AI Secures $7 Million to Revolutionize 3D Creation
- Gen Digital Inc. Set to ANNOUNCE Q2 Results Soon
- Positive Insights from Phase 3 ASPEN Study on Brensocatib
- Realty Income Declares 652nd Monthly Dividend Payment
- City Office REIT Unveils Earnings Release and Call Details
- Omnicom Plans Earnings Call for Third Quarter Performance
- Compass Inc. Prepares for Exciting Q3 Earnings Announcement
- HealthSherpa Introduces New ICHRA Marketplace for Employers
- ODDSworks and RAW iGaming Partner for Game Distribution
- BH Properties Expands Presence with New Oregon Campus Acquisition
- Citius Pharmaceuticals Faces Challenges Amid Stock Low
- BAIYU Holdings Resumes Trading Amid Strategic Developments
- Oracle Corporation Surges: Stock Reaches New Heights of $174.06
- Vaccination Insights for Older Adults: Protecting Health
- InMode Ltd. Experiences Market Fluctuations and Growth Plans